Atossa Therapeutics (ATOS) - Long-Term Debt to Capital

Atossa Therapeutics (ATOS) management is focused on developing breast tumor therapies, striving for success in clinical trials. However, business stability is limited by uncertainty surrounding the drug endoxifen and a potential FDA rejection, which triggers price volatility. The company relies on external contractors to conduct tests while adhering to strict regulations. This price chart reflects that the separate_debt_long_eq metric stands at 0.00.

This ratio measures the proportion of liabilities with a maturity exceeding one year relative to market capitalization, determining the company's degree of dependence on debt financing over the long term. By analyzing the trajectory of long-term debt to equity, an investor can assess the financial stability of Atossa Therapeutics (ATOS) during the implementation of its strategy to bring Endoxifen to market, which confirms the asset's low default risk.